Notices
19 September 2017
Necessity of More Sensitivity Analyses and Interpretations From Public Health Perspectives
Vasveebye Sonoo, Jay V. Kumar, Xibei Liu, Johnson Ukken, Mary Froehlich, Ji Won Yoo – 18 September 2017
Reply
Barret Rush, Keith R. Walley, Leo Anthony Celi, Neil Rajoriya, Mayur Brahmania – 18 September 2017
MicroRNA‐506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation
Oihane Erice, Patricia Munoz‐Garrido, Javier Vaquero, Maria J. Perugorria, Maite G. Fernandez‐Barrena, Elena Saez, Alvaro Santos‐Laso, Ander Arbelaiz, Raul Jimenez‐Agüero, Joaquin Fernandez‐Irigoyen, Enrique Santamaria, Verónica Torrano, Arkaitz Carracedo, Meenakshisundaram Ananthanarayanan, Marco Marzioni, Jesus Prieto, Ulrich Beuers, Ronald P. Oude Elferink, Nicholas F. LaRusso, Luis Bujanda, Jose J.G. Marin, Jesus M.
Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome‐wide association study
Mei‐Hsuan Lee, Yu‐Han Huang, Hsuan‐Yu Chen, Seik‐Soon Khor, Ya‐Hsuan Chang, Yu‐Ju Lin, Chin‐Lan Jen, Sheng‐Nan Lu, Hwai‐I Yang, Nao Nishida, Masaya Sugiyama, Masashi Mizokami, Yong Yuan, Gibert L'Italien, Katsushi Tokunaga, Chien‐Jen Chen, for the REVEAL‐HCV Cohort Study Group – 16 September 2017 – We conducted a genome‐wide association study to discover genetic variants associated with hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC). We genotyped 502 HCC cases and 749 non‐HCC controls using the Axiom‐CHB genome‐wide array.
Radiosensitization by inhibiting DNA repair: Turning the spotlight on homologous recombination
Bhanu P. Venkatesulu, Sunil Krishnan – 16 September 2017
Developing a prediction model for cardiovascular risk after orthotopic liver transplantation
Fu‐Shan Xue, Ya‐Yang Liu, Gui‐Zhen Yang – 16 September 2017
Reply
Lisa B. VanWagner, Hongyan Ning, Maureen Whitsett, Josh Levitsky, Sarah Uttal, John T. Wilkins, Michael M. Abecassis, Daniela P. Ladner, Anton I. Skaro, Donald M. Lloyd‐Jones – 16 September 2017
Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient
Julien Vionnet, Manuel Pascual, Barbara Testoni, Christophe Combet, Sébastien Godat, Sandrine Vijgen, Vincent Aubert, Laura Rubbia‐Brandt, Fabien Zoulim, Darius Moradpour – 16 September 2017 – Direct‐acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV‐HCV‐coinfected patients treated with DAAs.
Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient
Julien Vionnet, Manuel Pascual, Barbara Testoni, Christophe Combet, Sébastien Godat, Sandrine Vijgen, Vincent Aubert, Laura Rubbia‐Brandt, Fabien Zoulim, Darius Moradpour – 16 September 2017 – Direct‐acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV‐HCV‐coinfected patients treated with DAAs.